V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003654 | 320002219 | 1.55 | null | Curative (C) | 2015-06-06 | 2015-06-21 | Ipilimumab | 02 | Y | 320023610 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003655 | 320002220 | null | 51.8 | Palliative (P) | 2015-01-23 | 2015-01-28 | Carboplatin + Liposomal Doxorubicin | 2 | N | 320023613 | CVD |
| 320003656 | 320002221 | 1.78 | 92.8 | Palliative (P) | 2013-11-22 | 2013-11-26 | Carboplatin+Fluorouracil 4 or 5 day | 2 | N | 320023614 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003657 | 320002221 | 1.7 | 97 | Palliative (P) | 2016-07-28 | 2016-08-18 | CETUXIMAB + RT | N | N | 320023614 | CARBOPLATIN + ETOPOSIDE |
| 320003658 | 320002221 | 1.69 | 68 | Palliative (P) | 2018-04-22 | 2018-05-21 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320023614 | IVA |
| 320003659 | 320002221 | 0 | 78.8 | Palliative (P) | 2017-09-01 | 2017-09-01 | Carboplatin + Etoposide iv&po | N | N | 320023614 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003660 | 320002222 | 1.61 | null | Neo-adjuvant (N) | null | 2013-02-06 | Temozolomide + RT | N | N | 320023648 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003661 | 320002223 | 1.6 | 61.1 | Disease modification (D) | 2018-09-01 | 2018-09-08 | FEC 100 | 2 | N | 320023650 | DOXORUBICIN + IFOSFAMIDE |
| 320003662 | 320002224 | 1.59 | 77.9 | null | 2015-12-20 | 2016-01-04 | Carbo F | N | Y | 320023651 | CISPLATIN + GEMCITABINE |
| 320003663 | 320002224 | 1.77 | 82.4 | Not known (9) | null | 2014-01-25 | MITOMYCIN | null | null | 320023651 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003664 | 320006364 | 1.6 | null | null | 2013-05-09 | 2013-05-09 | Carboplatin + Liposomal Doxorubicin | 02 | null | 320023661 | DOCETAXEL |
| 320003665 | 320002225 | null | null | Palliative (P) | 2014-07-01 | 2014-07-07 | CISPLATIN + GEMCITABINE | N | N | 320023669 | SUNITINIB |
| 320003666 | 320002225 | null | 59.5 | Palliative (P) | 2016-05-23 | 2016-07-01 | Capecitabine | N | N | 320023669 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003667 | 320002225 | 1.7 | 68 | Palliative (P) | 2014-03-08 | 2014-03-14 | Capecitabine + Cisplatin | 02 | N | 320023669 | ICON8B TRIAL |
| 320003669 | 320002226 | 1.68 | null | Palliative (P) | 2013-10-15 | 2013-11-11 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 320023682 | CISPLATIN + GEMCITABINE |
| 320003670 | 320002226 | 1.66 | 66.8 | Curative (C) | 2017-10-15 | 2017-10-19 | TIP | 02 | N | 320023682 | CAPECITABINE + CISPLATIN |
| 320003671 | 320002226 | 1.72 | 56 | Palliative (P) | 2017-01-20 | 2017-01-27 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320023682 | ICON8B TRIAL |
| 320003673 | 320002228 | 1.8 | null | null | 2014-08-22 | 2014-08-26 | Ipilimumab | null | null | 320023690 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 320003674 | 320002229 | 1.6 | 86.4 | Palliative (P) | 2017-08-04 | 2017-08-14 | RCEOP | N | N | 320023694 | PEMBROLIZUMAB |
| 320003675 | 320002230 | 1.67 | 55 | Palliative (P) | 2014-02-10 | 2015-02-20 | Cetuximab + Radiotherapy Load | 02 | N | 320023697 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003676 | 320002231 | 1.64 | null | null | null | 2017-09-06 | CAP | null | null | 320023703 | OXALIPLATIN + MDG |
| 320003677 | 320002232 | 1.56 | 98.799 | Curative (C) | null | 2013-07-26 | CETUXIMAB + RT | Y | null | 320023705 | CETUXIMAB + RT |
| 320003678 | 320002232 | 1.64 | 54 | Disease modification (D) | 2014-10-16 | 2014-10-30 | DOXORUBICIN | Y | N | 320023705 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003679 | 320002233 | 1.58 | 64 | Palliative (P) | 2017-03-26 | 2017-04-05 | Carbo F | Y | N | 320023709 | CARBO + FLUOROURACIL |
| 320003680 | 320002234 | 1.87 | 53.2 | Palliative (P) | 2017-07-31 | 2017-08-21 | Carboplatin + Etoposide iv&po | N | N | 320023712 | IVA |
| 320003682 | 320002236 | 1.71 | 65 | Neo-adjuvant (N) | 2013-02-03 | 2013-02-07 | null | 02 | N | 320023720 | TEMOZOLOMIDE + RT |
| 320003683 | 320002236 | 1.6 | 84 | Neo-adjuvant (N) | 2014-07-28 | 2014-08-03 | Temozolomide + RT | N | N | 320023720 | CETUXIMAB + RT |
| 320003684 | 320002236 | 1.67 | 57.3 | Neo-adjuvant (N) | 2017-05-04 | 2017-05-14 | Carboplatin + Vinorelbine Oral | 02 | N | 320023720 | CISPLATIN + GEMCITABINE |
| 320003685 | 320002236 | 1.58 | 50.2 | Neo-adjuvant (N) | 2013-02-22 | 2013-02-28 | Bevacizumab+Carbo+Gemcitabine | N | N | 320023720 | CVP R |
| 320003686 | 320002236 | 1.69 | null | Neo-adjuvant (N) | 2017-02-24 | 2017-02-26 | CYCLOPHOSPHAMIDE + EPIRUBICIN | N | N | 320023720 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003687 | 320002236 | null | 47.4 | Neo-adjuvant (N) | 2015-05-20 | 2015-06-02 | CISPLATIN + GEMCITABINE | N | N | 320023720 | CVD |
| 320003688 | 320002237 | null | 82.4 | Neo-adjuvant (N) | 2017-02-01 | 2017-02-01 | TIP | N | N | 320023764 | ECX |
| 320003689 | 320002238 | null | 55.2 | Palliative (P) | 2018-01-18 | 2018-01-31 | ICON8 TRIAL | N | N | 320023766 | ICON8B TRIAL |
| 320003690 | 320002238 | 1.87 | 66 | Palliative (P) | 2018-01-21 | 2018-02-04 | Cisplatin + Docetaxel +Fluorouracil | 2 | N | 320023766 | CISPLATIN + GEMCITABINE |
| 320003691 | 320002238 | 1.64 | 84 | Palliative (P) | 2016-02-06 | 2016-04-05 | Oxaliplatin + Modified de Gramont | N | N | 320023766 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003692 | 320002239 | 1.65 | 100 | Palliative (P) | 2015-12-30 | 2016-01-14 | CAPECITABINE + OXALIPLATIN | 02 | N | 320023771 | BCG |
| 320003693 | 320002240 | 1.75 | 93.1 | Curative (C) | 2013-03-10 | 2013-03-11 | CETUXIMAB | Y | N | 320023774 | CETUXIMAB + CISPLATIN + FU |
| 320003694 | 320002241 | 1.61 | 72 | Adjuvant (A) | null | 2015-12-11 | Cisplatin + Vinorelbine (IV) | N | N | 320023775 | OCTREOTIDE |
| 320003695 | 320002242 | 1.64 | 51 | Adjuvant (A) | 2016-08-26 | 2016-10-05 | Bevacizumab + CARBOPLATIN + GEMCITABINE | N | Y | 320023777 | CISPLATIN + ETOPOSIDE |
| 320003696 | 320002243 | 1.75 | 54 | Curative (C) | 2018-12-11 | 2018-12-13 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 320023778 | TRIAL |
| 320003697 | 320002244 | 1.87 | 50.1 | Neo-adjuvant (N) | 2016-04-13 | 2016-05-04 | CARBOPLATIN + RT | N | N | 320023780 | CISPLATIN + PEMETREXED |
| 320003698 | 320002244 | 1.61 | 0 | Adjuvant (A) | null | 2017-02-23 | Capecitabine + Oxaliplatin 21day | N | N | 320023780 | FEC + DOCETAXEL |
| 320003699 | 320002244 | 1.61 | 45.7 | Disease modification (D) | 2015-12-21 | 2015-12-31 | FEC 100 | Y | N | 320023780 | ICON8B TRIAL |
| 320003700 | 320002245 | 1.74 | 106.2 | Adjuvant (A) | 2015-06-03 | 2015-06-17 | Cisplatin + Etoposide (3 day) | N | N | 320023796 | POUT TRIAL |
| 320003701 | 320002246 | 1.79 | 54 | Neo-adjuvant (N) | 2013-04-08 | 2013-04-17 | Capecitabine (14 days)+Carboplatin | 02 | N | 320023797 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003702 | 320002247 | 1.8 | 72 | Curative (C) | 2014-08-29 | 2014-09-25 | POUT TRIAL | N | Y | 320023805 | EPIRUBICIN |
| 320003703 | 320002248 | null | 60 | Palliative (P) | null | 2014-02-13 | TRASTUZUMAB | N | null | 320023808 | CETUXIMAB + RT |
| 320003704 | 320002249 | 1.57 | 54 | Palliative (P) | 2017-12-20 | 2017-12-20 | Rituximab | 02 | N | 320023819 | CARBO + FLUOROURACIL |
| 320003705 | 320002249 | null | 80.8 | Palliative (P) | 2017-08-03 | 2017-08-18 | BCG Intravesical | N | null | 320023819 | FLUOROURACIL |
| 320003706 | 320002249 | 1.61 | 0 | Neo-adjuvant (N) | 2016-05-26 | 2016-06-01 | IMATINIB | 2 | null | 320023819 | BCG |